Baltimore Washington Financial Advisors Inc. lowered its stake in Celgene Corp. (NASDAQ:CELG) by 5.6% during the third quarter, Holdings Channel reports. The fund owned 28,094 shares of the biopharmaceutical company’s stock after selling 1,665 shares during the period. Baltimore Washington Financial Advisors Inc.’s holdings in Celgene Corp. were worth $2,937,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Carmignac Gestion boosted its position in Celgene Corp. by 28.1% in the second quarter. Carmignac Gestion now owns 9,708,359 shares of the biopharmaceutical company’s stock valued at $957,535,000 after buying an additional 2,127,659 shares in the last quarter. Bank of Montreal Can purchased a new position in Celgene Corp. during the second quarter valued at $117,274,000. Thrivent Financial for Lutherans boosted its position in Celgene Corp. by 3,648.3% in the second quarter. Thrivent Financial for Lutherans now owns 1,082,701 shares of the biopharmaceutical company’s stock valued at $106,825,000 after buying an additional 1,053,816 shares during the last quarter. Pictet Asset Management Ltd. boosted its position in Celgene Corp. by 99.8% in the second quarter. Pictet Asset Management Ltd. now owns 2,017,809 shares of the biopharmaceutical company’s stock valued at $212,919,000 after buying an additional 1,008,034 shares during the last quarter. Finally, Winslow Capital Management LLC boosted its position in Celgene Corp. by 21.1% in the second quarter. Winslow Capital Management LLC now owns 5,341,255 shares of the biopharmaceutical company’s stock valued at $526,807,000 after buying an additional 931,307 shares during the last quarter. 76.43% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Celgene Corp. (NASDAQ:CELG)

Shares of Celgene Corp. (NASDAQ:CELG) traded up 1.52% during trading on Tuesday, reaching $122.13. 4,450,492 shares of the company traded hands. The firm has a market capitalization of $94.68 billion, a price-to-earnings ratio of 46.38 and a beta of 1.71. The company has a 50 day moving average price of $108.88 and a 200 day moving average price of $106.73. Celgene Corp. has a 12-month low of $93.05 and a 12-month high of $127.00.

Celgene Corp. (NASDAQ:CELG) last issued its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.48 by $0.10. The company earned $2.98 billion during the quarter, compared to analysts’ expectations of $2.84 billion. Celgene Corp. had a net margin of 19.71% and a return on equity of 70.48%. The business’s revenue for the quarter was up 27.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.23 EPS. On average, equities analysts predict that Celgene Corp. will post $5.92 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Celgene Corp. (CELG) Shares Sold by Baltimore Washington Financial Advisors Inc.” was first posted by Daily Political and is the propert of of Daily Political. If you are reading this article on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this article can be viewed at http://www.dailypolitical.com/2016/11/29/celgene-corp-celg-shares-sold-by-baltimore-washington-financial-advisors-inc.html.

Several equities analysts have weighed in on CELG shares. Jefferies Group reiterated a “buy” rating on shares of Celgene Corp. in a research report on Tuesday, August 23rd. BTIG Research reiterated a “buy” rating and set a $138.00 price objective on shares of Celgene Corp. in a research report on Sunday, August 21st. Stifel Nicolaus reiterated a “buy” rating and set a $138.00 price objective on shares of Celgene Corp. in a research report on Tuesday, August 2nd. Zacks Investment Research upgraded shares of Celgene Corp. from a “hold” rating to a “buy” rating and set a $130.00 price objective on the stock in a research report on Friday, August 5th. Finally, Piper Jaffray Cos. set a $145.00 price objective on shares of Celgene Corp. and gave the stock a “buy” rating in a research report on Monday, August 15th. Four analysts have rated the stock with a hold rating and twenty-seven have issued a buy rating to the company. Celgene Corp. has a consensus rating of “Buy” and a consensus target price of $136.62.

In other news, Director Gilla Kaplan sold 9,710 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $106.44, for a total value of $1,033,532.40. Following the completion of the transaction, the director now directly owns 72,142 shares in the company, valued at approximately $7,678,794.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Corp /De/ Celgene bought 800,150 shares of the company’s stock in a transaction dated Monday, October 24th. The stock was purchased at an average price of $14.00 per share, with a total value of $11,202,100.00. The disclosure for this purchase can be found here. 0.97% of the stock is currently owned by insiders.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corp. (NASDAQ:CELG).

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with MarketBeat.com's FREE daily email newsletter.